
“The orphan drug designation is an important regulatory advancement as we further our development in recurrent glioblastoma multiforme, a disease that is uniformly fatal with limited treatment options,” said Gary Gordon, vice president, oncology clinical development, AbbVie. “We are pleased to continue developing ABT-414 in Phase 2 trials in patients with glioblastoma multiforme based on the results of our Phase 1 program.”
Results from the Phase 1 clinical program evaluating ABT-414 in patients with recurrent or unresectable glioblastoma multiforme were presented at the 50th American Society of Clinical Oncology (ASCO) meeting in Chicago earlier this year.
Date: August 4, 2014
Source: AbbVie